• What is CEBPA?
  • CEBPA in Acute Myeloid Leukemia
  • Clinical Trials


CCAAT/enhancer binding protein, alpha (CEBPA) is a gene that encodes a protein that functions as a transcription factor that contains a leucine zipper and identifies CCAAT motifs in the promoter regions of gene targets. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame insertions and deletions are observed in cancers such as hematopoietic and lymphoid cancers, cervical cancer, and intestinal cancer.

Last Updated: March 30, 2018

CEBPA in Acute Myeloid Leukemia

CEBPA mutations are observed in 8–19% of patients diagnosed with AML (Benthaus et al. 2008; Bienz et al. 2005; Forhling et al. 2004; Pabst et al. 2001; Schlenk et al. 2008). "AML with CEBPA biallelic mutation" is recognized as a separate entity under the 2016 World Health Organization (WHO) classification (Arber et al. 2016) and confers a favorable prognosis in absence of concurrent FLT3-ITD mutations. CEBPA mutations fall into class II of the “two-hit” theory of leukemogenesis.​

Last Updated: March 30, 2018

My Cancer Genome has released its new and improved cancer clinical trials search tool on our beta website. Please visit beta.padiracinnovation.org to check it out!

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.